BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Biomarin Pharmaceutical Inc's research and development for the three months ended in Jun. 2016 was $167.0 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2016 was $660.7 Mil.
This is the expense the company spent on research and development.
Biomarin Pharmaceutical Inc Research & Development for the trailing twelve months (TTM) ended in Jun. 2016 was 158.713 (Sep. 2015 ) + 176.118 (Dec. 2015 ) + 158.793 (Mar. 2016 ) + 167.039 (Jun. 2016 ) = $660.7 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Biomarin Pharmaceutical Inc Annual Data
|Research & Development||66.7||78.6||93.3||115.1||147.3||214.4||302.2||354.8||461.5||634.8|
Biomarin Pharmaceutical Inc Quarterly Data
|Research & Development||86.2||107.7||125.7||142.1||142.1||157.9||158.7||176.1||158.8||167.0|